|
1
|
Brooke JS: Advances in the microbiology of
Stenotrophomonas Maltophilia. Clin Microbiol Rev.
34(e0003019)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gajdács M and Urbán E: Epidemiological
trends and resistance associated with Stenotrophomonas
maltophilia Bacteremia: A 10-year retrospective cohort study in
a tertiary-care hospital in Hungary. Diseases. 7(41)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gröschel MI, Meehan CJ, Barilar I, Diricks
M, Gonzaga A, Steglich M, Conchillo-Solé O, Scherer IC, Mamat U,
Luz CF, et al: The phylogenetic landscape and nosocomial spread of
the multidrug-resistant opportunist Stenotrophomonas
maltophilia. Nat Commun. 11(2044)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hafiz TA, Aldawood E, Albloshi A, Alghamdi
SS, Mubaraki MA, Alyami AS and Aldriwesh MG: Stenotrophomonas
maltophilia epidemiology, resistance characteristics, and
clinical outcomes: Understanding of the recent three years's
trends. Microorganisms. 10(2506)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Saied WI, Merceron S, Schwebel C, Monnier
AL, Oziel J, Garrouste-Orgeas M, Marcotte G, Ruckly S, Souweine B,
Darmon M, et al: Ventilator-associated pneumonia due to
Stenotrophomonas maltophilia: Risk factors and outcome. J
Infect. 80:279–285. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chang YT, Lin CY, Chen YH and Hsueh PR:
Update on infections caused by Stenotrophomonas maltophilia
with particular attention to resistance mechanisms and therapeutic
options. Front Microbiol. 6(893)2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Guerci P, Bellut H, Mokhtari M, Gaudefroy
J, Mongardon N, Charpentier C, Louis G, Tashk P, Dubost C,
Ledochowski S, et al: Outcomes of Stenotrophomonas
maltophilia hospital-acquired pneumonia in intensive care unit:
A nationwide retrospective study. Crit Care. 23(371)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tamma PD, Aitken SL, Bonomo RA, Mathers
AJ, van Duin D and Clancy CJ: Infectious diseases society of
America guidance on the treatment of AmpC β-Lactamase-producing
Enterobacterales, Carbapenem-Resistant Acinetobacter
baumannii, and Stenotrophomonas maltophilia Infections.
Clin Infect Dis. 74:2089–2114. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Baidya A, Kodan P, Fazal F, Tsering S,
Menon PR, Jorwal P and Chowdhury UK: Stenotrophomonas
maltophilia: More than just a colonizer! Indian J Crit Care
Med. 23:434–436. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Singhal L, Kaur P and Gautam V:
Stenotrophomonas maltophilia: From trivial to grievous.
Indian J Med Microbiol. 35:469–479. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mojica MF, Humphries R, Lipuma JJ, Mathers
AJ, Rao GG, Shelburne SA, Fouts DE, Van Duin D and Bonomo RA:
Clinical challenges treating Stenotrophomonas maltophilia
infections: An update. JAC Antimicrob Resist.
4(dlac040)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Morris S and Cerceo E: Trends,
epidemiology, and management of multi-drug resistant gram-negative
bacterial infections in the hospitalized setting. Antibiotics
(Basel). 9(196)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Marino A, Campanella E, Stracquadanio S,
Ceccarelli M, Zagami A, Nunnari G and Cacopardo B:
Corynebacterium striatum bacteremia during SARS-CoV2
Infection: Case report, literature review, and clinical
considerations. Infect Dis Rep. 14:383–390. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Marino A, Munafò A, Zagami A, Ceccarelli
M, Campanella E, Cosentino F, Moscatt V, Cantarella G, Di Mauro R,
Bernardini R, et al: Ampicillin plus ceftriaxone therapy against
Enterococcus faecalis endocarditis: A case report,
guidelines considerations, and literature review. IDCases.
28(e01462)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cillóniz C, Dominedò C and Torres A: An
overview of guidelines for the management of hospital-acquired and
ventilator-associated pneumonia caused by multidrug-resistant
Gram-negative bacteria. Curr Opin Infect Dis. 32:656–662.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
El-Sokkary R, Uysal S, Erdem H, Kullar R,
Pekok AU, Amer F, Grgić S, Carevic B, El-Kholy A, Liskova A, et al:
Profiles of multidrug-resistant organisms among patients with
bacteremia in intensive care units: An international ID-IRI survey.
Eur J Clin Microbiol Infect Dis. 40:2323–2334. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kalil AC, Metersky ML, Klompas M,
Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP,
Bartlett JG, Carratalà J, et al: Management of adults with
hospital-acquired and ventilator-associated pneumonia: 2016
clinical practice guidelines by the infectious diseases society of
America and the American thoracic society. Clin Infect Dis.
63:e61–e111. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Papazian L, Klompas M and Luyt CE:
Ventilator-associated pneumonia in adults: A narrative review.
Intensive Care Med. 46:888–906. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Marino A, Campanella E, Ceccarelli M,
Larocca L, Bonomo C, Micali C, Munafò A, Celesia BM, Nunnari G and
Cacopardo B: Sarilumab administration in patients with severe
COVID-19: A report of four cases and a literature review. World
Acad Sci J. 4(24)2022.
|
|
20
|
Ippolito M, Misseri G, Catalisano G,
Marino C, Ingoglia G, Alessi M, Consiglio E, Gregoretti C,
Giarratano A and Cortegiani A: Ventilator-associated pneumonia in
patients with covid-19: A systematic review and meta-analysis.
Antibiotics (Basel). 10(545)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Rouzé A, Martin-Loeches I, Povoa P, Makris
D, Artigas A, Bouchereau M, Lambiotte F, Metzelard M, Cuchet P,
Geronimi CB, et al: Relationship between SARS-CoV-2 infection and
the incidence of ventilator-associated lower respiratory tract
infections: A European multicenter cohort study. Intensive Care
Med. 47:188–198. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Blonz G, Kouatchet A, Chudeau N, Pontis E,
Lorber J, Lemeur A, Planche L, Lascarrou JB and Colin G:
Epidemiology and microbiology of ventilator-associated pneumonia in
COVID-19 patients: A multicenter retrospective study in 188
patients in an un-inundated French region. Crit Care.
25(72)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Patro S, Sarangi G, Das P, Mahapatra A,
Mohapatra D, Paty B and Chayani N: Bacteriological profile of
ventilator-associated pneumonia in a tertiary care hospital. Indian
J Pathol Microbiol. 61:375–379. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ferrer M, Liapikou A, Valencia M,
Esperatti M, Theessen A, Martinez JA, Mensa J and Torres A:
Validation of the American Thoracic Society-Infectious Diseases
Society of America guidelines for hospital-acquired pneumonia in
the intensive care unit. Clin Infect Dis. 50:945–952.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Restrepo MI, Peterson J, Fernandez JF, Qin
Z, Fisher AC and Nicholson SC: Comparison of the bacterial etiology
of early-onset and late-onset ventilator-associated pneumonia in
subjects enrolled in 2 large clinical studies. Respir Care.
58:1220–1225. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Looney WJ, Narita M and Mühlemann K:
Stenotrophomonas maltophilia: An emerging opportunist human
pathogen. Lancet Infect Dis. 9:312–323. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang N, Tang C and Wang L: Risk factors
for acquired Stenotrophomonas maltophilia pneumonia in
intensive care unit: A systematic review and meta-analysis. Front
Med (Lausanne). 8(808391)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang Y, Wang Y, Rong H, Guo Z, Xu J and
Huang X: Risk factors of lower respiratory tract infection caused
by Stenotrophomonas maltophilia: Systematic review and
meta-analysis. Front Public Health. 10(5410)2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nakamura R, Oota M, Matsumoto S, Sato T
and Yamano Y: In vitro activity and in vivo efficacy of cefiderocol
against Stenotrophomonas maltophilia. Antimicrob Agents
Chemother. 65:e01436–e01420. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Stracquadanio S, Torti E, Longshaw C,
Henriksen AS and Stefani S: In vitro activity of cefiderocol and
comparators against isolates of gram-negative pathogens from a
range of infection sources: SIDERO-WT-2014-2018 studies in Italy. J
Glob Antimicrob Resist. 25:390–398. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Petraitis V, Petraitiene R, Kavaliauskas
P, Naing E, Garcia A, Georgiades BN, Echols R, Bonomo RA, Yamano Y,
Satlin MJ and Walsh TJ: Efficacy of cefiderocol in experimental
Stenotrophomonas maltophilia pneumonia in persistently
neutropenic rabbits. Antimicrob Agents Chemother.
66(e0061822)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hotta G, Matsumura Y, Kato K, Nakano S,
Yunoki T, Yamamoto M, Nagao M, Ito Y, Takakura S and Ichiyama S:
Risk factors and outcomes of Stenotrophomonas maltophilia
bacteraemia: A comparison with bacteraemia caused by pseudomonas
aeruginosa and acinetobacter species. PLoS One.
9(e112208)2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ba BB, Feghali H, Arpin C, Saux MC and
Quentin C: Activities of ciprofloxacin and moxifloxacin against
Stenotrophomonas maltophilia and emergence of resistant
mutants in an in vitro pharmacokinetic-pharmacodynamic model.
Antimicrob Agents Chemother. 48:946–953. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Gil-Gil T, Martínez JL and Blanco P:
Mechanisms of antimicrobial resistance in Stenotrophomonas
maltophilia: A review of current knowledge. Expert Rev Anti
Infect Ther. 18:335–347. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Prawang A, Chanjamlong N, Rungwara W,
Santimaleeworagun W, Paiboonvong T, Manapattanasatein T,
Pitirattanaworranat P, Kitseree P and Kanchanasurakit S:
Combination therapy versus monotherapy in the treatment of
Stenotrophomonas maltophilia infections: A systematic review
and meta-analysis. Antibiotics (Basel). 11(1788)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Shah MD, Coe KE, El Boghdadly Z, Wardlow
LC, Dela-Pena JC, Stevenson KB and Reed EE: Efficacy of combination
therapy versus monotherapy in the treatment of Stenotrophomonas
maltophilia pneumonia. J Antimicrob Chemother. 74:2055–2059.
2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bivona DA, Mirabile A, Bonomo C, Bonacci
PG, Stracquadanio S, Marino A, Campanile F, Bonaccorso C, Fortuna
CG, Stefani S, et al: Heteroaryl-ethylenes as new effective agents
for high priority gram-positive and gram-negative bacterial
clinical isolates. Antibiotics. 11(767)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Stracquadanio S, Bonomo C, Marino A,
Bongiorno D, Privitera GF, Bivona DA, Mirabile A, Bonacci PG and
Stefani S: Acinetobacter baumannii and Cefiderocol, between
Cidality and Adaptability. Microbiol Spectr.
10(e0234722)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Marino A, Stracquadanio S, Campanella E,
Munafò A, Gussio M, Ceccarelli M, Bernardini R, Nunnari G and
Cacopardo B: Intravenous fosfomycin: A potential good partner for
cefiderocol. Clinical experience and considerations. Antibiotics
(Basel). 12(49)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
The European Committee on Antimicrobial
Susceptibility Testing. Breakpoint tables for interpretation of
MICs and zone diameters. Version 13.0, 2023. http://www.eucast.org.
|
|
41
|
Biagi M, Tan X, Wu T, Jurkovic M,
Vialichka A, Meyer K, Mendes RE and Wenzler E: Activity of
potential alternative treatment agents for Stenotrophomonas
maltophilia isolates nonsusceptible to levofloxacin and/or
Trimethoprim-sulfamethoxazole. J Clin Microbiol. 58:e01603–e01619.
2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wu RX, Yu CM, Hsu ST and Wang CH:
Emergence of concurrent levofloxacin- and
trimethoprim/sulfamethoxazole-resistant Stenotrophomonas
maltophilia: Risk factors and antimicrobial sensitivity pattern
analysis from a single medical center in Taiwan. J Microbiol
Immunol Infection. 55:107–113. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chung HS, Kim K, Hong SS, Hong SG, Lee K
and Chong Y: The sul1 gene in Stenotrophomonas maltophilia
with high-level resistance to trimethoprim/sulfamethoxazole. Ann
Lab Med. 35:246–249. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hu LF, Chen GS, Kong QX, Gao LP, Chen X,
Ye Y and Li JB: Increase in the prevalence of resistance
determinants to trimethoprim/sulfamethoxazole in clinical
Stenotrophomonas maltophilia isolates in China. PLoS One.
11(157693)2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Toleman MA, Bennett PM, Bennett DMC, Jones
RN and Walsh TR: Global emergence of trimethoprim/sulfamethoxazole
resistance in Stenotrophomonas maltophilia mediated by
acquisition of sul Genes. Emerg Infect Dis. 13:559–565.
2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Yin C, Yang W, Meng J, Lv Y, Wang J and
Huang B: Co-infection of Pseudomonas aeruginosa and
Stenotrophomonas maltophilia in hospitalised pneumonia
patients has a synergic and significant impact on clinical
outcomes. Eur J Clin Microbiol Infect Dis. 36:2231–2235.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
McDaniel MS, Schoeb T and Swords WE:
Cooperativity between Stenotrophomonas maltophilia and
Pseudomonas aeruginosa during polymicrobial airway
infections. Infect Immun. 88:e00855–e00819. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mcdaniel MS, Lindgren NR, Billiot CE,
Valladares KN, Sumpter NA and Swords WE: Pseudomonas
aeruginosa promotes persistence of Stenotrophomonas
maltophilia via increased adherence to depolarized respiratory
epithelium. Microbiol Spectr. 11(e0384622)2022.PubMed/NCBI View Article : Google Scholar
|
